Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 23, 2010, Pages 7046-7049

  Lee, Junwon ^a   Kim, Jong Yup ^a   Choi, Jungsub ^a   Lee, Sung Han ^a   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

Author keywords

Dapagliflozin; Diabetes; Glucoside; Pyrimidine; SGLT

Indexed keywords

4 CHLORO 3 (5 (METHYLTHIO)PYRIMIDIN 2 YL)METHYLPHENYL; ANTIDIABETIC AGENT; CANAGLIFOZIN; DAPAGLIFOZIN; GLUCOSIDE; PYRIMIDINE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DIABETES MELLITUS; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; STRUCTURE ACTIVITY RELATION;

ANIMALS; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; MICE; PYRIMIDINES; SODIUM-GLUCOSE TRANSPORTER 2; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78149284310     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.103     Document Type: Article

References (21)

1. International Diabetes Federation. Diabetes Atlas, 4th ed.; International Diabetes Federation: Montreal, Canada, 2009.
2. A. Dwarakanathan J. Insur. Med. 38 2006 20
3. B. Mackenzie, and D.D. Loo J. Biol. Chem. 20 1996 32678
4. O.W. Moe, C.A. Berry, and F.C. Rector B.M. Brenner, F.C. Rector, The Kidney 5th ed. 2000 WB Saunders Philadelphia 375 415
5. B.A. Ellsworth, W. Meng, M. Patel, R.N. Girotra, G. Wu, P. Sher, D. Hagan, M. Obermeier, W.G. Humphreys, J.G. Robertson, A. Wang, S. Han, T. Waldron, N.N. Morgan, J.M. Whaley, and W.N. Washburn Bioorg. Med. Chem. Lett. 18 2008 4770
6. W. Meng, B.A. Ellsworth, A.A. Nirschl, P.J. McCann, M. Patel, R.N. Girotra, G. Wu, P.M. Sher, E.P. Morrison, A.A. Biller, R. Zahler, P.P. Deshpande, A. Pullockaran, D.L. Hagan, N. Morgan, J.R. Taylor, M.T. Obermeier, W.G. Humphreys, A. Khanna, L. Discenza, J.G. Robertson, A. Wang, S. Han, J.R. Wetterau, E.B. Janovitz, O.P. Flint, J.M. Whaley, and W.N. Washburn J. Med. Chem. 51 2008 1145
7. W.N. Washburn J. Med. Chem. 52 2009 1785
8. According to a report from Business Wire on June 26, 2010, dapagliflozin as add on therapy to insulin demonstrated improved glycemic control in patients with type 2 diabetes inadequately controlled with insulin.
9. S. Nomura, S. Sakamaki, M. Hongu, E. Kawanshi, Y. Koga, T. Sakamoto, Y. Yamamoto, K. Ueta, H. Kimata, K. Nakayama, and M. Tsuda-Tsukimoto J. Med. Chem. 2010 10.1021/jm100332n
10. (a) Boehringer Ingelheim Pharmaceuticals, www.clinicaltrials.gov, 2010, NCT01164501. (b) Lexicon Pharmaceuticals, www.clinicaltrials.gov, 2009, NCT00962065. (c) Astellas Pharma Inc., www.clinicaltrials.gov, 2010, NCT01135433. (d) Mascitti, V. Presented at the 240th American Chemical Society National Meeting and Exposition, Boston, MA, August 22-26, 2010; Medi-151.
11. J. Lee, S.-H. Lee, H.J. Seo, E.-J. Son, S.H. Lee, M.E. Jung, M. Lee, H.-K. Han, J. Kim, J. Kang, and J. Lee Bioorg. Med. Chem. 18 2010 2178
12. M.J. Kim, J. Lee, S.Y. Kang, S.-H. Lee, E.-J. Son, M.E. Jung, S.H. Lee, K.-S. Song, M. Lee, H.-K. Han, J. Kim, and J. Lee Bioorg. Med. Chem. Lett. 20 2010 3420
13. S.Y. Kang, K.-S. Song, J. Lee, S.-H. Lee, and J. Lee Bioorg. Med. Chem. 18 2010 6069
14. N. Miyaura, and A. Suzuki Chem. Rev. 95 1995 2457
15. 3OD) δ 8.76 (s, 2H), 2.57 (s, 3H).
16. 14C-AMG) uptake assay.
17. 16,17
18. S. Han, D.L. Hagan, J.R. Taylor, L. Xin, W. Meng, S.A. Biller, J.R. Wetterau, W.N. Washburn, and J.M. Whaley Diabetes 57 2008 1723
19. K. Katsuno, Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura, and M. Isaji J. Pharmacol. Exp. Ther. 320 2007 323
20. +.
21. 50 = 0.49 ± 0.04 nM) in each different assay. Thus, we trust that all SAR discussions in the manuscript are scientifically valid.